References
- Gerlach J. Depot neuroleptics in relapse prevention. I. Advantages and disadvantages. ICP 1995;55:17–20
- Kane JM, Aguglia, Altamura AC, et al. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 1998;8:55–66
- Gilbert PL, Harris MJ, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 1995;52:173–88
- Mann JJ. How medication compliance affects outcome. Psychiatr Ann 1986;16:567–70
- Csernansky JG, Mahmoud R, Brenner R, et al. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia. N Engl J Med 2002;346:16–22
- Geddes J. Prevention of relapse in schizophrenia. N Engl J Med 2002;346:56–8
- Davis JM, Matalon L, Wananabe MD, et al. Depot antipsychotic drugs. Place in therapy. Drugs 1994;47:741–73
- Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analyses: combined results of the North American trials. J Clin Psychiatry 1997;58:538–46
- Kane JM, Eerdekens M, Keith SJ, et al. Efficacy and safety of a novel long-acting risperidone microspheres formulation. Schizophrenia Res 2002;53(Suppl):174 (Abstr B63)
- Eerdekens M, Fleischhacker WW, Xie Y, et al. Long-term safety of long-acting risperidone microspheres. Schizophrenia Res 2002;53 (Suppl):174 (Abstr B64)
- Chue P, Eerdekens M, Augustyns I, et al. Efficacy and safety of long-acting risperidone microspheres and risperidone oral tablets. Schizophrenia Res 2002;53(Suppl):174–5 (Abstr B65)
- Summary of Manufacturer’s Product Characteristics for Risperdal ConstaÔ.
- Kay SR, Fiszbein A, Opler LA. The positive-negative syndrome scale (PANSS) for schizophrenia. Schizophrenia Bull 1987;13:261–76
- US Department of Health EaW. ECDEU Assessment Manual for Psychopharmacology. Publication ADM 76–338 ed. Washington DC: US Department of Health, Education and Welfare, 1976
- Chouinard G, Ross-Chouinard A, Annable L, et al. Extrapyramidal symptom rating scale. Can J Neurol Sci 1980;7:233
- Bloch Y, Mendlovic S, Strupinsky S, et al. Injections of depot antipsychotic medications in patients suffering from schizophrenia: Do they hurt? J Clin Psychiatry 2001;62:855–9
- Hamann GL, Egan TM, Wells BG, et al. Injections site reactions after intramuscular administration of haloperidol decanoate 100 mg/ml. J Clin Psychiatry 1990;51:502–4
- Walburn J, Gray R, Gournay K, et al. Systematic review of patient and nurse attitudes to depot antipsychotic medication. Br J Psychiatry 2001;179:300–7
- Hagström P, Hansson B-M. Practical handling aspects of long-lasting risperidone microspheres (Risperdal Consta): an attitude survey. Nord J Psychiatry 2002;56:18
- Quartermaine S, Taylor R. A comparative study of depot injection techniques. Nurs Times 1995;91:36–9
- Dworkin RH. Pain sensitivity in schizophrenia: a neglected phenomenon and some implications. Schizophrenia Bull 1994;20:235–48
- Guieu R, Samuelian JC, Coulouvrant H. Objective evaluation of pain perception in patients with schizophrenia. Br J Psychiatry 1994;164:253–5
- Almond S, O’Donnell O. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol. Pharmacoeconomics 2000;17:383–9
- Davis JM. Maintenance therapy and the natural course of schizophrenia. J Clin Psychiatry 1985;46:18–21
- Chue PS, Devos E, Duchesne IY, et al. One year hospitalization rates in patients with schizophrenia during long-term treatment with long-acting risperidone. Value in Health 2002;5:229
- Llorca P-M, Devos E, Eerdekens M, et al. Rehospitalisation rates with long-acting risperidone injection are lower than those reported for other antipsychotics. Poster presentation at the XXIII CINP Congress, Montreal, Canada, June 23–27, 2002